FDA guidance aims to improve pregnancy safety data after approval
The FDA has finalized guidance to improve how pregnancy safety data are collected after a drug or biologic is approved. The agency says the goal is to fill evidence gaps left by preapproval studies, where pregnant people are often underrepresented or excluded.
